Cleared Traditional

K903122 - EQUATE(TM) AQR APO AL/B DUO CONTROL

K903122 is the FDA 510(k) clearance for EQUATE(TM) AQR APO AL/B DUO CONTROL by Binax, Inc.. It is a Class 2 Immunology device (product code DFC) cleared through the Traditional 510(k) pathway after a 17-day FDA review.

K903122 · Binax, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1990
Decision
17d
Days
Class 2
Risk

K903122 is an FDA 510(k) clearance for the EQUATE(TM) AQR APO AL/B DUO CONTROL. Classified as Lipoprotein, Low-density, Antigen, Antiserum, Control (product code DFC), Class II - Special Controls.

Submitted by Binax, Inc. (S. Portland, US). The FDA issued a Cleared decision on August 2, 1990 after a review of 17 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5600 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Binax, Inc. devices

Submission Details

510(k) Number K903122 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 16, 1990
Decision Date August 02, 1990
Days to Decision 17 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
87d faster than avg
Panel avg: 104d · This submission: 17d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DFC Lipoprotein, Low-density, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5600
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DFC Lipoprotein, Low-density, Antigen, Antiserum, Control

All 31
Devices cleared under the same product code (DFC) and FDA review panel - the closest regulatory comparables to K903122.
APOB
K983281 · Abbott Laboratories · Jan 1999
WAKO AUTOKIT APO B
K954657 · Wako Chemicals USA, Inc. · Dec 1995
IL TEST CALIBRATION SET APO A1B
K923079 · Instrumentation Laboratory CO · Feb 1993
QM300 CALIBRATOR F PACK
K883711 · Kallestad Diag, A Div. of Erbamont, Inc. · Sep 1988
QM300 CONTROL F PACK
K883712 · Kallestad Diag, A Div. of Erbamont, Inc. · Sep 1988
RAICHEM(TM) SPIA(TM) APO B REAGENTS
K872080 · Reagents Applications, Inc. · Jun 1987